Discover how SB Drug Discovery’s innovative cell-based tools, including stable GIP receptor and β-Arrestin cell lines, can advance your drug discovery efforts. By leveraging real-time monitoring of receptor-β-Arrestin interactions, biased signalling studies, and receptor internalization assays, SB Drug Discovery accelerates the development of novel therapeutics targeting metabolic disorders.
Introduction
Glucose-dependent insulinotropic polypeptide (GIP) receptor, a member of the G protein-coupled receptor (GPCR) family, serves as the primary mediator of GIP’s physiological effects. Through its activation, GIP receptor signalling influences various cellular pathways, including those involved in insulin release, adipogenesis, and gastrointestinal function. Found primarily in pancreatic β-cells and adipocytes, GIP receptors mediate insulin release and impact lipid metabolism, implicating them in the development of obesity and related metabolic disorders. Targeting GIP receptors presents a promising therapeutic strategy for managing obesity and type 2 diabetes, with pharmaceutical interventions offering potential avenues for improving metabolic health and addressing obesity-related complications. Understanding the intricate mechanisms underlying GIP receptor signalling provides valuable insights into the pathophysiology of metabolic diseases and facilitates the development of novel therapeutic interventions.
